B. Riley started coverage on shares of Trevi Therapeutics (NASDAQ:TRVI – Get Rating) in a research note issued to investors on Wednesday, The Fly reports. The brokerage issued a buy rating and a $6.00 price target on the stock. B. Riley also issued estimates for Trevi Therapeutics’ Q1 2023 earnings at ($0.06) EPS, Q2 2023 […]
B. Riley initiated coverage on shares of Trevi Therapeutics (NASDAQ:TRVI – Get Rating) in a research note released on Wednesday morning, The Fly reports. The firm issued a buy rating and a $6.00 price objective on the stock. B. Riley also issued estimates for Trevi Therapeutics’ Q1 2023 earnings at ($0.06) EPS, Q2 2023 earnings […]
Equities research analysts at B. Riley started coverage on shares of Trevi Therapeutics (NASDAQ:TRVI – Get Rating) in a note issued to investors on Wednesday, The Fly reports. The brokerage set a “buy” rating on the stock. A number of other equities analysts have also recently weighed in on the stock. Needham & Company LLC […]
Fireside chat will be held on Monday, April 17, 2023, at 11:00 a.m. ET
NEW HAVEN, Conn., April 11, 2023 /PRNewswire/ Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company. | April 11, 2023
Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Rating) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 114,800 shares, a growth of 73.2% from the February 28th total of 66,300 shares. Based on an average trading volume of 105,400 shares, the short-interest ratio is presently 1.1 days. […]